Menopause

Clinics in Geriatric Medicine

Volumn 19, Issue 3, 2003, Pages 483-506

  Wilson, Margaret Mary G ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANGELICA SINENSIS EXTRACT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; ESTROGEN; GESTAGEN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; LASOFOXIFENE; LINSEED OIL; MEGESTROL ACETATE; METHYLDOPA; OMEGA 3 FATTY ACID; PAROXETINE; POLYCARBOPHIL; PRIMROSE OIL; PROGESTERONE; RALOXIFENE; RED CLOVER EXTRACT; REPLENS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; VENLAFAXINE;

ANAMNESIS; BREAST CANCER; CALCIUM INTAKE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLIMACTERIUM; CLINICAL TRIAL; COGNITIVE DEFECT; CUSHING SYNDROME; DELIRIUM; DEMENTIA; DEPRESSION; DIET THERAPY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN ACTIVITY; EXERCISE; FEMALE SEXUAL DYSFUNCTION; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPOTENSION; LABORATORY TEST; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL CYCLE; META ANALYSIS; MOOD DISORDER; OSTEOPOROSIS; OVARY FUNCTION; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIMARY PREVENTION; PROTEIN INTAKE; REVIEW; RISK FACTOR; SCREENING; SEX THERAPY; SLEEP DISORDER; THROMBOEMBOLISM; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA ATROPHY;

AGED; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0042665911     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00102-7     Document Type: Review

References (128)

1. Hargrove JT, Eisenberg E. Menopause. Med Clin North Am 1995;79:1337-56.
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571-80.
3. McKinlay S, Brambilla PJ, Posnere JG. The normal menopause transition. Maturitas 1992;14:13-5.
4. Harlow B, Signorello LB. Factors associated with early menopause. Maturitas 2000;35:3-9.
5. Wise PM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science 1996;273:67-70.
6. Lacker HM, Beers WH, Meuli LE, Akin E. A theory of follicle selection I: Hypothesis and examples. Biol Reprod 1987;37:570-80.
7. Greenwald GS, Roy SK. Menopause. In: Knobil E, Neils JD, editors. The physiology of reproduction. New York: Raven Press; 1994. p. 629-724.
8. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987;65:1231-7.
9. Southworth MB, Matsamuto AM, Gross KM, Soules MR, Bremner WJ. The importance of signal pattern in the transmission of endocrine information: pituitary gonadotropin responses to continuous and pulsatile gonadotropin releasing hormone. J Clin Endocrinol Metab 1991;72:1286-9.
10. Burger H. Diagnostic role of follicle stimulating hormone (FSH) measurements during the menopausal transition: an analysis of FSH, oestradiol and inhibin. Eur J Endocrinol 1994;130:38-42.
11. Hoomerman EMD, Buijs RM. Vasopressin fiber pathways in the rat brain following suprachiasmatic nucleus lesioning. Brain Res 1982;243:235-41.
12. Van der Beek EM, Wiegant VM, van der Donk HA, van der Hurk R, Buijs RM. Lesions of the suprachiasmatic nucleus indicate the presence of a direct vasoactive intestinal polypeptide-containing projection to gonadotropin releasing hormone neurons in the female rat. J Neuroendocrinol 1993;5:137-44.
13. Salisbury RL, Krieg Jr. RJ, Seibel HR. Effect of arginine vasotocin, oxytocin and arginine vasopressin on steroid induced surges of luteinizing hormone and prolactin in ovariectomized rats. Acta Endocrinol 1980;94:166-73.
14. Walsh B, Schiff I. Vasomotor flushes. Ann N Y Acad Sci 1990;592:346-56.
15. Bachmann G. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180: S312-6.
16. Thompson B, Hart SA, Durno D. Menopausal age and symptomatology in a general practice. J Biosoc Sci 1973;5:71-82.
17. Freedman RR. Physiology of hot flashes. American Journal of Human Biology 2001;13:453-64.
18. Silva NL, Boulant JA. Effects of testosterone, estradiol and temperature on neurons in preoptic tissue slices. Am J Physiol 1986;250(4 pt 2):R625-32.
19. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8.
20. Freedman RR, Woodward S. Core body temperature during menopausal hot flushes. Fertil Steril 1996;65:1141-4.
21. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26(5):573-9.
22. Freedman RR. Biochemical, metabolic and vascular mechanisms in menopausal hot flushes. Fertil Steril 1998;70:332-7.
23. 2-adrenergic responsiveness in menopausal hot flushes: pharmacological and biochemical studies. In: Lomax P, Schonbaum E, editors. Thermoregulation: the pathophysiological basis of clinical disorders. Basal: Karger; 1992. p. 6-10.
24. 2-Adrenergic mechanisms in menopausal hot flushes. Obstet Gynecol 1990;76:573-8.
25. Maas J. MHPG: basic mechanism and psychopathology. New York: Academic Press; 1983.
26. Leckman JF, Maas J, Redmond Jr DE, Heniger GR. Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: preliminary report. Life Sci 1980;26:2179-85.
27. Stone SC, Mickal A, Tye PJ. Postmenopausal symptomatology, maturation index, and plasma estrogen levels. Obstet Gynecol 1975;45:625-7.
28. Rekers H, Drogendijk AC, Valkenburg HA, Riphagen F. The menopause, urinary incontinence and other symptoms of the genito-urinary tract. Maturitas 1992;15:101-11.
29. Milsom I, Ekelund P, Molander U, Arvidsson L, Areskoug B. The influence of age, parity oral contraception, hysterectomy and menopause on the prevalence of urinary incontinence in women. J Urol 1993;149:1459-62.
30. Hallstrom T, Samuelsson S. Changes in women's sexual desire in middle life: the longitudinal study of women in Gothenburg. Arch Sex Behav 1990;19:259-68.
31. Hawton K, Gath D, Day A. Sexual function in a community sample of middle-aged women with partners: effects of age, marital, socio-economic, psychiatric, gynecological and menopausal factors. Arch Sex Behav 1994;23:375-95.
32. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
33. Greendale GA, Hogan P, Shumaker S. Sexual functioning in postmenopausal women: the postmenopausal estrogen/progesfin interventions trial. J Womens Health 1996;5:445-58.
34. Dennerstein L, Smith A, Morse C, Burger H. Sexuality and the menopause. J Psychosom Obstet Gynecol 1994;15:59-66.
35. Koste A, Garde K. Sexual desire and menopausal development: a prospective study of Danish women born in 1936. Maturitas 1993;16:49-60.
36. Hutchinson KA. Androgens and sexuality. Am J Med 1995;98(supp 1A):111S-8S.
37. Ciocca DR, Vargas Roig LM. Estrogen receptors in human non-target tissues: biological and clinical implications. Endocr Rev 1995;16:35-57.
38. Weiland N, Orikasa C, Hayashi S, McEwen B. Distridution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J Comp Neurol 1997;388:603-12.
39. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic density during the estrous cycle in the rat. J Comp Neurol 1993;336:293-306.
40. Lustig RH. Sex hormone modulation of neural development in vitro. Hormon Behav 1994;28:383-95.
41. Woolley CS, Gould E, Frankfurt M, McEwen BS. Naturally occurring fluctuation in dendritic spine density on adult hippocampal neurons. J Neurosci 1990;10:4025-39.
42. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994;644:305-12.
43. Henderson VW. Estrogen, cognition and a woman's risk of Alzheimer's disease. Am J Med 1997;103:11S-8S.
44. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. estrogen regulates metabolism of Alzheimer amyloid β-protein. J Biol Chem 1994;269:13065-8.
45. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993;41:217-9.
46. Mooradian AD. Antioxidant effects of steroids. J Steroid Biochem Mol Biol 1993;45:509-11.
47. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA 2000;283:1007-15.
48. LeBlanc E, Janowsky J, Benjamin KS, Nelso H. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489-99.
49. Shaver JL, Zenk SN. Sleep disturbance in menopause, Journal of Women's Health and Gender-based Medicine 2000;9:109-18.
50. Baker A, Simpson S, Dawson D. Sleep disruption and mood changes associated with menopause. J Psychosom Res 1997;43:359-69.
51. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988;11:556-61.
52. Polo-Kantola P, Saaresranta T, Polo O. Aetology and treatment of sleep disturbances during perimenopause and postmenopause. CNS Drugs 2001;15:445-52.
53. Lamberg L. 'Old and gray and full of sleep'? Not always. JAMA 1997;278:1302-4.
54. Halbreich U. Role of estrogen in postmenopausal depression. Neurology 1997;48(supp 7): S16-20.
55. Kaufert PA, Gilbert P, Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992;14:143-55.
56. Mitchell ES, Woods NF. Symptom experiences of midlife women: observations from the Seattle midlife women's health study. Maturitas 1996;25:1-10.
57. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-20.
58. Stewart DE, Boydell KM. Psychological distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 1993;23:157-62.
59. Santoro N, Brown JR, Adel T, Skumick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-501.
60. Stellato RK, Crawford SL, McKinlay SM, Longcope CL. Can follicle stimulating hormone be used to define menopausal status. Endocr Pract 1998;4:137-41.
61. Keating N, Cleary P, Aossi A, Zaslavsky A, Ayanlan J. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intem Med 1999;130:545-53.
62. Mendelsohn M, Karas R. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
63. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-41.
64. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA 2000;283:1007-15.
65. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized placebo-controlled trial. Neurology 2000;54:295-301.
66. Hulley S, Grady D, Bush T, et al. For the HERS Research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research group. JAMA 1998;280:605-13.
67. Grady D, Herrington D, Bittner V, et al. For the HERS Research group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA 2002;288:49-57.
68. Writing group for the Women's health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
69. Women's health initiative study group. Design of the women's health initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
70. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9.
71. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-7.
72. Greendale G, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998;92:982-8.
73. Laufer L, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-6.
74. Steams V, Hayes DF. Cooling off hot flashes. J Clin Oncol 2002;20:1436-8.
75. Albertazzi P, Pansini F, Bonaccorsi G, Forini E, DeAloysio D. The effect of dietary soy supplementation on hot flashes. Obstet Gynecol 1998;91:6-11.
76. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999;6:7-13.
77. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000;7:105-11.
78. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases postmenopausal hot flashes: effect of soy and wheat. Maturitas 1995;21:189-95.
79. Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 2000;43:162-83.
80. Nachtigall LE. Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
81. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. Obstet Gynecol 1996;88:745-9.
82. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women.: a meta analysis. Obstet Gynecol 1994;83:12-8.
83. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause. Fertil Steril 2001;76:456-60.
84. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas 1996;23:159-68.
85. Dei M, Vemi A, Bigozzi L, Bruni V. Sex steroids and libido. Eur J Contracept Reprod Health Care 1997;2:253-8.
86. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomised women. Psychosom Med 1987;49:397-409.
87. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2468-82.
88. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein on serum lipids. N Engl J Med 1995;333:276-82.
89. Dagenais GR, Marchioli R, Yusuf S, Tognoni G. Beta-carotene, vitamin C, vitamin E, and cardiovascular diseases. Curr Cardiol Rep 2000;2:293 -9.
90. Christen WG, Gaziano JM, Hennekens CH. Design of physicians health study II: a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease and eye disease, and review of results of completed trials. Ann Epidemiol 2000;10:125-34.
91. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Povenzione trial. Gruppo Italiano per lo studio della Sopravvivenza nell'infarcto mcardico. Lancet 1999;354:447-55.
92. Burr ML, Fehily AM, Gilbert JF, et al. Effect of changes in fat, fish and fiber intakes on death and myocardial infarction. Lancet 1989;2:757-61.
93. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89.
94. Siris EE, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001;286:2815-22.
95. Riggs BL, Melton LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 suppl):505S-11S.
96. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
97. Burger H, de Laet CE, van Daele PL, et al. Risk factors for increased bone loss in an elderly population: The Rotterdam Study. Am J Epidemiol 1998;147:871-9.
98. Pollitzer WS, Anderson JJ. Ethnic and genetic differences in bone mass: a review with a hereditary vs environmental perspective. Am J Clin Nutr 1989;50:1244-59.
99. Hurley DL, Khosla S. Update on primary osteoporosis. Mayo Clin Proc 1997;72:943-9.
100. Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986;314:1676-86.
101. Riggs BL, Melton III LJ. Clinical heterogeneity of involutional osteoporosis. J Clin Endocrinol Metab 1990;70:1229-32.
102. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitrom 1999;2:343-50.
103. Osteoporosis Prevention, Diagnosis and Therapy: NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001;285:785-95.
104. Rehman Q, Lang T, Modin G, Lane NE. Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor ofprevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone replacement therapy. Arthritis Rheum 2002;46:1292-7.
105. Messinger-Rapport BJ, Thacker HL. Prevention for the older woman: a practical guide to prevention and treatment of osteoporosis. Geriatrics 2002;57:16-27.
106. Chapuy MC, Arlot ME, Dubocuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
107. Chapuy MC, Arlot ME, Delmas P, Meunier P. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2.
108. New SA, Smith R, Brown JC, Reid DM. Positive association between fruit and vegetable consumption and bone mass in late postmenopausal and elderly women. Osteoporosis 2002;13(suppl 1):S77.
109. New SA. The role of the skeleton in acid-base homeostasis. Proc Nutr Soc 2002;61:151-64.
110. Potter SM, Baum JA, Tong H, Stillman RJ, Shay NF, Erdmfan Jr JW. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(6 suppl):1375S-9S.
111. Chow R, Harrison JE, Notarius C. Effect of two randomised exercise programmes on bone mass of healthy postmenopausal women. BMJ 1987;295:1441-4.
112. Kohrt B, Snead DB, Slatopolsky E, Birge Jr. SJ. Additive effects of weight bearing exercise and estrogen on bone mineral density in older women. J Bone Miner Res 1995;10:1303-11.
113. Krolner B, Toft B. Vertebral bone loss: an unheeded side effect of therapeutic bed rest. Clin Sci 1983;64:537-40.
114. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208.
115. Delmas PD, Bjamason M, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, anduterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
116. Ettinger B, Black DM, Mitlak BH, et al. For the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results of a 3-year randomized clinical trial. JAMA 1999;282:637-45.
117. Cummings SR, Eckert S, Krueger KA, et al. For the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. The effect of Raloxifene on breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97.
118. Moffet A. Emerging data and experience with lasofoxifene: highlights from clinical trials. Presented at From Research to Clinical Evidence: defining the standard for postmenopausal women. Satellite Symposium of IOF - World Congress on Osteoporosis. Amsterdam, the Netherlands. May 10, 2002.
119. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD. Lasofoxifene (CP-336,156) protects against the age related changes in bone mass, bone strength and total serum cholesterol in intact aged male rats. J Bone Miner Res 2001;16:765-73.
120. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Study Group. Lancet 1996;348:1535-41.
121. Cummings SR, Black DM, Thomspon DE, et al. Effect of alendronate on risk of fractures in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial Study Group. JAMA 1998;280:2077-82.
122. Karpf PD, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by Alendronate. A meta analysis. Alendronate Osteoporosis Treatment Study Group. JAMA 1997;277:1159-64.
123. Reginster JY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of Risendronate on vertebral fractures in women with established osteoporosis. Vertebral Efficacy with Risendronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
124. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2001;22:15-28.
125. Watts NB, Li Z, Hoseyni MS, et al. Efficacy of once-a-week risendronate in reducing vertebral fracture risk. Osteoporosis Int 2002;13(suppl):S33.
126. Thiebaud D, Bruckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307.
127. Reid MD. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-62.
128. Chestnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures (PROF) study. Am J Med 2000;109:267-76.